About Phillips Medisize
Phillips Medisize is a company based in Chippenham (United Kingdom) founded in 1997 was acquired by Phillips Medisize in May 2025. It operates as a Professional Services, and Reseller / Distribution. Phillips Medisize has raised $15.21 million across 2 funding rounds from investors including Boehringer Ingelheim, Molex and Philip Morris International. Phillips Medisize has completed 3 acquisitions, including Activaero, Skyepharma and Syqe. Phillips Medisize offers products and services including Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector. Phillips Medisize operates in a competitive market with competitors including Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others.
- Headquarter Chippenham, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Phillips Medisize – A Molex Company
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$15.21 M (USD)
in 2 rounds
-
Latest Funding Round
$21.76 M (USD), Post-IPO
Nov 26, 2007
-
Investors
Boehringer Ingelheim
& 4 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Activaero
& 2 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Phillips Medisize
Phillips Medisize offers a comprehensive portfolio of products and services, including Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Devices for delivering dry powder inhalation therapies effectively.
Inhalers providing metered doses for respiratory treatment solutions.
Nebulizer using vibrating mesh for efficient drug delivery.
Smart autoinjector designed for precise drug administration ease.
Unlock access to complete
Funding Insights of Phillips Medisize
Phillips Medisize has successfully raised a total of $15.21M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.76 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $21.8M
-
First Round
First Round
(24 Apr 2001)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2007 | Amount | Post-IPO - Phillips Medisize | Valuation |
investors |
|
| Apr, 2001 | Amount | Series B - Phillips Medisize | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Phillips Medisize
Phillips Medisize has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Boehringer Ingelheim, Molex and Philip Morris International. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across the UK.
|
Founded Year | Domain | Location | |
|
Generic drugs and clinical research services are provided globally.
|
Founded Year | Domain | Location | |
|
Communication equipment manufacturer
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Phillips Medisize
Phillips Medisize has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Activaero, Skyepharma and Syqe. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Precise dosing inhaler for medical cannabis is developed.
|
2011 | ||||
|
Controlled breathing technologies for inhaler devices were developed.
|
2004 | ||||
|
Developer of small molecule based oral and inhalation products for the treatment of various diseases
|
1996 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Phillips Medisize
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Phillips Medisize Comparisons
Competitors of Phillips Medisize
Phillips Medisize operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| domain | founded_year | HQ Location |
Company specializing in development of Biosimilars
|
|
| domain | founded_year | HQ Location |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
CDMO and analytical services for peptide development are provided.
|
|
| domain | founded_year | HQ Location |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| domain | founded_year | HQ Location |
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Phillips Medisize
Frequently Asked Questions about Phillips Medisize
When was Phillips Medisize founded?
Phillips Medisize was founded in 1997 and raised its 1st funding round 4 years after it was founded.
Where is Phillips Medisize located?
Phillips Medisize is headquartered in Chippenham, United Kingdom.
Who is the current CEO of Phillips Medisize?
Will Downie is the current CEO of Phillips Medisize.
Is Phillips Medisize a funded company?
Phillips Medisize is a funded company, having raised a total of $15.21M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15.21M, raised on Apr 24, 2001.
What does Phillips Medisize do?
Phillips Medisize, incorporating Vecturas expertise since 2025, is focused on inhaled drug development. Services are offered in formulation science, device technology, and development for inhalation therapies. Solutions are provided for small molecules, biologics, and complex combinations across pMDI, DPI, nasal inhalers, and nebulizers. Contributions have been made to 13 launched inhaled medicines, benefiting millions globally. Sectors served include pharmaceutical and medtech industries with a focus on respiratory health solutions.
Who are the top competitors of Phillips Medisize?
Phillips Medisize's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
What products or services does Phillips Medisize offer?
Phillips Medisize offers Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector.
How many acquisitions has Phillips Medisize made?
Phillips Medisize has made 3 acquisitions, including Activaero, Skyepharma, and Syqe.
Who are Phillips Medisize's investors?
Phillips Medisize has 5 investors. Key investors include Boehringer Ingelheim, Molex, Philip Morris International, NVM Private Equity, and Phillips Medisize.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.